These data suggest that inhibition of the PI3-kinase/mTOR pathway and of anti-apoptotic members of the BCL-2 family may be a reasonable approach to counteract malignant cell growth in ALL. This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.